MetLife Investment Management LLC Lowers Stake in Insulet Co. (NASDAQ:PODD)

MetLife Investment Management LLC lessened its holdings in Insulet Co. (NASDAQ:PODD) by 2.3% in the 3rd quarter, Holdings Channel.com reports. The firm owned 21,405 shares of the medical instruments supplier’s stock after selling 509 shares during the quarter. MetLife Investment Management LLC’s holdings in Insulet were worth $4,982,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the business. QRG Capital Management Inc. purchased a new stake in shares of Insulet in the third quarter valued at approximately $297,000. Diversified Trust Co increased its holdings in Insulet by 90.9% in the 2nd quarter. Diversified Trust Co now owns 9,130 shares of the medical instruments supplier’s stock worth $1,842,000 after acquiring an additional 4,348 shares in the last quarter. Linden Thomas Advisory Services LLC increased its holdings in Insulet by 65.8% in the 2nd quarter. Linden Thomas Advisory Services LLC now owns 8,812 shares of the medical instruments supplier’s stock worth $1,778,000 after acquiring an additional 3,497 shares in the last quarter. Assenagon Asset Management S.A. raised its position in Insulet by 38.8% during the second quarter. Assenagon Asset Management S.A. now owns 179,393 shares of the medical instruments supplier’s stock worth $36,202,000 after acquiring an additional 50,101 shares during the period. Finally, Fisher Asset Management LLC lifted its holdings in Insulet by 0.9% during the third quarter. Fisher Asset Management LLC now owns 351,100 shares of the medical instruments supplier’s stock valued at $81,719,000 after purchasing an additional 3,113 shares in the last quarter.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Piper Sandler boosted their target price on shares of Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 17th. BTIG Research boosted their price objective on Insulet from $260.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, November 8th. Raymond James raised their target price on Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a research report on Monday, October 14th. Canaccord Genuity Group boosted their price target on Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Finally, Barclays raised their price objective on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Three analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $253.27.

Insulet Stock Down 0.1 %

PODD stock opened at $266.78 on Monday. The firm has a market cap of $18.71 billion, a PE ratio of 45.68, a PEG ratio of 4.08 and a beta of 1.22. Insulet Co. has a one year low of $160.19 and a one year high of $279.40. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.80 and a current ratio of 3.68. The firm’s 50 day moving average price is $244.40 and its 200-day moving average price is $214.14.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.